ATE455767T1 - Heterozyklische vegfr-2 kinase inhibitoren - Google Patents

Heterozyklische vegfr-2 kinase inhibitoren

Info

Publication number
ATE455767T1
ATE455767T1 AT03761106T AT03761106T ATE455767T1 AT E455767 T1 ATE455767 T1 AT E455767T1 AT 03761106 T AT03761106 T AT 03761106T AT 03761106 T AT03761106 T AT 03761106T AT E455767 T1 ATE455767 T1 AT E455767T1
Authority
AT
Austria
Prior art keywords
vegfr
heterocyclic
kinase inhibitors
kinase
inhibitors
Prior art date
Application number
AT03761106T
Other languages
English (en)
Inventor
Robert Borzilleri
John Tokarski
Rajeev Bhide
Peter Zheng
Ligang Qian
Zhen-Wei Cai
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE455767T1 publication Critical patent/ATE455767T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
AT03761106T 2002-06-20 2003-06-18 Heterozyklische vegfr-2 kinase inhibitoren ATE455767T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39081302P 2002-06-20 2002-06-20
PCT/US2003/019243 WO2004001059A2 (en) 2002-06-20 2003-06-18 Heterocyclic inhibitors of kinases

Publications (1)

Publication Number Publication Date
ATE455767T1 true ATE455767T1 (de) 2010-02-15

Family

ID=30000629

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03761106T ATE455767T1 (de) 2002-06-20 2003-06-18 Heterozyklische vegfr-2 kinase inhibitoren

Country Status (14)

Country Link
US (2) US7084160B2 (de)
EP (1) EP1513818B1 (de)
JP (1) JP4477492B2 (de)
AR (1) AR040272A1 (de)
AT (1) ATE455767T1 (de)
AU (1) AU2003251559A1 (de)
DE (1) DE60331061D1 (de)
ES (1) ES2337246T3 (de)
IS (1) IS7599A (de)
NO (1) NO330043B1 (de)
PE (1) PE20040581A1 (de)
PL (1) PL374272A1 (de)
TW (1) TW200401638A (de)
WO (1) WO2004001059A2 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US6242469B1 (en) * 1996-12-03 2001-06-05 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
TW200401638A (en) * 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
CN1678734B (zh) * 2002-06-27 2012-12-12 韦尔瓦制药有限公司 分化调节试剂及其应用
CA2496477C (en) * 2002-08-23 2012-10-16 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7691886B2 (en) 2003-07-11 2010-04-06 Merck Patent Gmbh Benzimidazole derivatives as raf kinase inhibitors
US7718676B2 (en) * 2003-10-23 2010-05-18 Ab Science 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
GB0326601D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
US7449167B2 (en) * 2004-07-08 2008-11-11 Air Products And Chemicals, Inc. Catalyst and process for improving the adiabatic steam-reforming of natural gas
AU2006226861B2 (en) 2005-03-22 2012-08-16 Dana-Farber Cancer Institute, Inc. Treatment of protein degradation disorders
JP5204643B2 (ja) * 2005-04-04 2013-06-05 アブ サイエンス 置換オキサゾール誘導体、およびチロシンキナーゼ阻害薬としてのそれらの使用
WO2006134989A1 (ja) * 2005-06-15 2006-12-21 Kyowa Hakko Kogyo Co., Ltd. 含窒素複素環化合物
WO2007067257A2 (en) 2005-12-02 2007-06-14 Vanderbilt University Broad-emission nanocrystals and methods of making and using same
EP1976885B1 (de) 2005-12-21 2014-12-03 Amgen Research (Munich) GmbH Pharmazeutische antikörperzusammensetzungen mit resistenz gegenüber löslichem cea
CA2632924A1 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Chemical compounds
ES2481413T3 (es) 2006-02-14 2014-07-30 The President And Fellows Of Harvard College Inhibidores de histona desacetilasa
JP5441416B2 (ja) 2006-02-14 2014-03-12 プレジデント アンド フェロウズ オブ ハーバード カレッジ 二官能性ヒストンデアセチラーゼインヒビター
AU2007238785B2 (en) * 2006-04-13 2013-02-07 Agnieszka Ambrozak Tetrahalogenated compounds useful as inhibitors of angiogenesis
EP2019674B1 (de) 2006-05-03 2016-11-23 The President and Fellows of Harvard College Histondeacetylase- und tubulindeacetylase-hemmer
EP2032989B2 (de) 2006-06-30 2015-10-28 Merck Sharp & Dohme Corp. Igfbp2-biomarker
JP5244118B2 (ja) 2006-11-10 2013-07-24 ブリストル−マイヤーズ スクイブ カンパニー 新規キナーゼ阻害剤
JP5286281B2 (ja) * 2007-01-05 2013-09-11 ブリストル−マイヤーズ スクイブ カンパニー アミノピラゾールキナーゼ阻害剤
WO2008084103A1 (en) * 2007-01-12 2008-07-17 Ab Science Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors
CA2701128A1 (en) 2007-10-01 2009-04-09 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
PE20121470A1 (es) 2007-10-26 2012-11-18 Univ California Compuestos de diarilhidantoina como antagonistas del receptor de androgeno
CA2731730C (en) 2008-07-23 2017-06-13 President And Fellows Of Harvard College Deacetylase inhibitors and uses thereof
GB0815781D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815784D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815782D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401614A1 (de) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Verfahren zur identifizierung von mesenchymähnlichen tumorzellen oder deren bildung hemmenden stoffen
US8716344B2 (en) 2009-08-11 2014-05-06 President And Fellows Of Harvard College Class- and isoform-specific HDAC inhibitors and uses thereof
CA2784807C (en) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
EP2702173A1 (de) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Verwendung von emt-gensignaturen bei der entdeckung von krebswirkstoffen, -diagnostika und -behandlungen
CN103597074A (zh) 2011-06-16 2014-02-19 Isis制药公司 成纤维细胞生长因子受体4表达的反义调节
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2016018795A1 (en) * 2014-07-28 2016-02-04 The General Hospital Corporation Histone deacetylase inhibitors
WO2016160617A2 (en) 2015-03-27 2016-10-06 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
EP3347018B1 (de) 2015-09-09 2021-09-01 Dana-Farber Cancer Institute, Inc. Hemmer von cyclinabhängigen kinasen

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0841008A (ja) * 1994-07-29 1996-02-13 Ono Pharmaceut Co Ltd 一酸化窒素合成酵素阻害剤
US6262096B1 (en) * 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
DE69923681T2 (de) * 1998-06-18 2006-01-12 Bristol-Myers Squibb Co. Kohlenstoff substituierte aminothiazole als inhibitoren von cyclin-abhängigen kinasen
US6214852B1 (en) * 1998-10-21 2001-04-10 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
AUPP873799A0 (en) * 1999-02-17 1999-03-11 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
US6515004B1 (en) * 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6670357B2 (en) 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
TW200300350A (en) 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
RS92004A (en) 2002-04-23 2006-12-15 Bristol-Myers Squibb Company Pyrrolo-triazine aniline compounds useful as kinase inhibitors
ES2318122T3 (es) 2002-04-23 2009-05-01 Bristol-Myers Squibb Company Compuestos de aril cetona pirrolo-triazina utiles como inhibidores de quinasa.
TW200400034A (en) 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
TW200401638A (en) * 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
EP1543009A4 (de) 2002-08-02 2007-08-08 Bristol Myers Squibb Co Pyrrolotriazin-kinaseinhibitoren

Also Published As

Publication number Publication date
WO2004001059A2 (en) 2003-12-31
US20060135576A1 (en) 2006-06-22
US7547711B2 (en) 2009-06-16
WO2004001059A3 (en) 2004-03-04
AU2003251559A8 (en) 2004-01-06
AR040272A1 (es) 2005-03-23
EP1513818A4 (de) 2006-10-04
IS7599A (is) 2004-12-15
ES2337246T3 (es) 2010-04-22
JP4477492B2 (ja) 2010-06-09
JP2005533808A (ja) 2005-11-10
EP1513818B1 (de) 2010-01-20
NO330043B1 (no) 2011-02-07
DE60331061D1 (de) 2010-03-11
NO20045220L (no) 2005-01-19
PL374272A1 (en) 2005-10-03
US7084160B2 (en) 2006-08-01
EP1513818A2 (de) 2005-03-16
TW200401638A (en) 2004-02-01
AU2003251559A1 (en) 2004-01-06
US20040077696A1 (en) 2004-04-22
PE20040581A1 (es) 2004-09-08

Similar Documents

Publication Publication Date Title
ATE455767T1 (de) Heterozyklische vegfr-2 kinase inhibitoren
DK1534290T3 (da) Hidtil ukendte kinasehæmmere
CY2016042I1 (el) Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
DE60320933D1 (de) Rho-kinase inhibitoren
IS7667A (is) Nýjar bensimídazólafleiður
NO20041293L (no) Alkyn-aryl-fosfodiesterase-4-inhibitorer
DK1490355T3 (da) Indolylmaleimidderivater
DE602004018837D1 (de) Ptidase-iv-inhibitoren
DK1505963T3 (da) Hepatitis C-inhibitorer
DE602004025258D1 (de) Aminotriazol-verbindungen als proteinkinase-hemmer
DE602004017623D1 (de) N-substituierte pyrazolyl-amidyl-benzimidazolyl-c-kit-inhibitoren
ATE433449T1 (de) Kinaseinhibitoren
ATE386518T1 (de) Benzimidazolderivate
DE602004019555D1 (de) Heterocyclische 7-aminoalkylidenylchinolone und -naphthyridone
IS7833A (is) Efnasambönd með sameinaða heteróhringi
ATE393159T1 (de) Heterobicyclische pyrazolderivate als kinaseinhibitoren
PL378116A1 (pl) Heterocykliczne inhibitory kinazy
DE60322544D1 (de) Glycinamid-derivate als raf-kinase-hemmer
ATE366242T1 (de) 5-substituierte chinazolinonderivate
NO20044269L (no) Smamolekylaere inntrengningsinhibitorer
DE60319836D1 (de) Heterocyclische kondensierte pyrazolderivate als kinaseinhibitoren
DE60334703D1 (de) Heterocyclische derivate
SE0203606D0 (sv) Heterocyclic compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties